377 related articles for article (PubMed ID: 30578436)
21. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
[TBL] [Abstract][Full Text] [Related]
22. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
23. Determinants of recurrent ventricular arrhythmia or death in 300 consecutive patients with ischemic heart disease who experienced aborted sudden death: data from the Leiden out-of-hospital cardiac arrest study.
Kiès P; Boersma E; Bax JJ; van der Burg AE; Bootsma M; van Erven L; van der Wall EE; Schalij MJ
J Cardiovasc Electrophysiol; 2005 Oct; 16(10):1049-56. PubMed ID: 16191114
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
[TBL] [Abstract][Full Text] [Related]
25. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
[TBL] [Abstract][Full Text] [Related]
26. Risk of death without appropriate defibrillator shock in patients with advanced renal dysfunction.
Goldenberg I; Mor T; Nof E; Younis A; Berkovitch A; Rosso R; Barsheshet A; Suleiman M; Beinart R
Europace; 2019 Mar; 21(3):459-464. PubMed ID: 30689821
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of potassium levels in patients with ventricular tachyarrhythmias.
Schupp T; Bertsch T; von Zworowsky M; Kim SH; Weidner K; Rusnak J; Barth C; Reiser L; Taton G; Reichelt T; Ellguth D; Engelke N; Bollow A; Akin M; Mashayekhi K; Große Meininghaus D; Borggrefe M; Akin I; Behnes M
Clin Res Cardiol; 2020 Oct; 109(10):1292-1306. PubMed ID: 32236716
[TBL] [Abstract][Full Text] [Related]
28. Electrical storm is associated with impaired prognosis compared to ventricular tachyarrhythmias.
Behnes M; Müller J; Ellguth D; Schupp T; Taton G; Reiser L; Engelke N; Reichelt T; Bollow A; Kim SH; Barth C; Saleh A; Rusnak J; Weidner K; Nienaber CA; Mashayekhi K; Akin M; Bertsch T; Weiß C; Borggrefe M; Akin I
Int J Cardiol; 2019 Oct; 292():119-125. PubMed ID: 31076250
[TBL] [Abstract][Full Text] [Related]
29. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
[TBL] [Abstract][Full Text] [Related]
30. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
[TBL] [Abstract][Full Text] [Related]
31. Digitalis therapy in patients with ventricular tachyarrhythmias.
Schupp T; Müller J; von Zworowsky M; Abumayyaleh M; Weidner K; Rusnak J; Mashayekhi K; Bertsch T; Akin I; Behnes M
Scand Cardiovasc J; 2022 Dec; 56(1):198-207. PubMed ID: 35792713
[No Abstract] [Full Text] [Related]
32. Association of device detected atrial and ventricular tachyarrhythmia with adverse events in patients with an implantable cardioverter-defibrillator.
Abbas H; Younis A; Goldenberg I; McNitt S; Aktas MK; Tabaja C; Ojo A
J Cardiovasc Electrophysiol; 2024 Jun; 35(6):1203-1211. PubMed ID: 38606650
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
34. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
[TBL] [Abstract][Full Text] [Related]
35. Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients.
Robin J; Weinberg K; Tiongson J; Carnethon M; Reddy M; Ciaccio C; Quadrini M; Hsu J; Fan J; Choi P; Kadish A; Goldberger J; Passman R
Heart Rhythm; 2006 Oct; 3(10):1196-201. PubMed ID: 17018351
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
[TBL] [Abstract][Full Text] [Related]
37. Appropriate therapy but not inappropriate shocks predict survival in implantable cardioverter defibrillator patients.
Dichtl W; Wolber T; Paoli U; Brüllmann S; Stühlinger M; Berger T; Spuller K; Strasak A; Pachinger O; Haegeli LM; Duru F; Hintringer F
Clin Cardiol; 2011 Jul; 34(7):433-6. PubMed ID: 21678454
[TBL] [Abstract][Full Text] [Related]
38. Non-ischemic compared to ischemic cardiomyopathy is associated with increasing recurrent ventricular tachyarrhythmias and ICD-related therapies.
Rusnak J; Behnes M; Weiß C; Nienaber C; Reiser L; Schupp T; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Weidner K; Akin M; Mashayekhi K; Borggrefe M; Akin I
J Electrocardiol; 2020; 59():174-180. PubMed ID: 32179288
[TBL] [Abstract][Full Text] [Related]
39. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death.
Kutyifa V; Vermilye K; Daimee UA; McNitt S; Klein H; Moss AJ
Europace; 2018 Sep; 20(FI2):f225-f232. PubMed ID: 29905788
[TBL] [Abstract][Full Text] [Related]
40. Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease.
Hess PL; Hellkamp AS; Peterson ED; Sanders GD; Al-Khalidi HR; Curtis LH; Hammill BG; Pun PH; Curtis JP; Anstrom KJ; Hammill SC; Al-Khatib SM
Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):793-9. PubMed ID: 25038119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
